Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

RANI

STRONG SELL

Rani Therapeutics Holdings, Inc. · Healthcare · United States · $117M · Avg Vol: $762K/d

2
StockRank
Get insider-trade alerts
Q
23
V
27
M
16
P/E (TTM)
—
ROE
-240.0%
D/E
0.1x
Dividend %
—
Dir. Trades · 180d
+$50K · −$301.1 →
Buybacks · 180d
None →
Loading 1Y...
PRICE (1Y)+6.6%
0.630.700.770.830.90Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$0.81
RSI (14)
60.7
52W High
$3.87
From 52W High
0.2%

SCORE BREAKDOWN

Quality
23
ROIC
-74.4%9.2
ROE
-240.0%3.3
GP/Assets
5.4%20.3
Op. Margin
-488.2%10.2
FCF/Assets
-32.1%9.6
Piotroski
239.0
Int. Cover
-16.8x19.6
D/E Ratio
0.11x61.6
Current Ratio
3.40x58.7
Value
27
P/E (TTM)
—N/A
EV/EBITDA
-1.6x25.0
P/FCF
—N/A
P/B
3.0x44.2
P/S
36.9x12.0
Div Yield
—N/A
Momentum
16
52W High %
21%3.8
RS 6M
-50%14.9
SMA 50/200
0.68x7.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+21%35.1
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$117M
P/E (Forward)
-4.0x
Gross Margin
100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RANI are excluded.

TickerCompanyMkt CapStockRankSignal
RANIRani Therapeutics Holdings, Inc.(you)$117M2STRONG SELL
2592.HKCloudbreak Pharma Inc.$110M1STRONG SELL
SPRBSpruce Biosciences, Inc.$119M5STRONG SELL
GUTSFractyl Health, Inc.$123M5STRONG SELL
ONCYOncolytics Biotech Inc.$97M5STRONG SELL
PLYXPolaryx Therapeutics, Inc.$102M6STRONG SELL
ALDXAldeyra Therapeutics, Inc.$92M4STRONG SELL
GNLXGenelux Corporation$130M7STRONG SELL
NTHINeOnc Technologies Holdings, Inc.$89M1STRONG SELL
HUMAHumacyte, Inc.$168M2STRONG SELL

Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%

Rani Therapeutics Holdings, Inc. (RANI) — Stock Score Summary

Rani Therapeutics Holdings, Inc. (RANI) has a MoatMap StockRank of 2/100 based on Quality (23/100), Value (27/100), and Momentum (16/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price$0.81
Market Cap$117M
P/E (Forward)-3.99
Price/Book2.99
Return on Equity-240.0%
Return on Invested Capital-74.4%
Debt/Equity0.11x
Gross Margin100.0%
Operating Margin-488.2%
Revenue Growth893.0%
Free Cash Flow$-19M

Rani Therapeutics Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Rani Therapeutics Holdings, Inc.’s (RANI) StockRank?
MoatMap’s StockRank for Rani Therapeutics Holdings, Inc. (RANI) is 2/100, with a Strong Sell signal. It is a composite of Quality (23), Value (27), and Momentum (16) factor ranks across MoatMap’s 20,000+ stock universe.
Does Rani Therapeutics Holdings, Inc. have an economic moat?
Rani Therapeutics Holdings, Inc. (RANI) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Rani Therapeutics Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Rani Therapeutics Holdings, Inc. (RANI) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Rani Therapeutics Holdings, Inc. in?
Rani Therapeutics Holdings, Inc. (RANI) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRANI deep dive reportAI ChampionsHow we score stocksSense-check another stock